These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 27145977)

  • 1. Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose.
    Krieter P; Chiang N; Gyaw S; Skolnick P; Crystal R; Keegan F; Aker J; Beck M; Harris J
    J Clin Pharmacol; 2016 Oct; 56(10):1243-53. PubMed ID: 27145977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device.
    Krieter PA; Chiang CN; Gyaw S; McCann DJ
    J Clin Pharmacol; 2019 Aug; 59(8):1078-1084. PubMed ID: 30861160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose-a randomized controlled trial.
    Skulberg AK; Åsberg A; Khiabani HZ; Røstad H; Tylleskar I; Dale O
    Addiction; 2019 May; 114(5):859-867. PubMed ID: 30644628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naloxone (Narcan) nasal spray for opioid overdose.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):1-2. PubMed ID: 26714239
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study.
    McDonald R; Lorch U; Woodward J; Bosse B; Dooner H; Mundin G; Smith K; Strang J
    Addiction; 2018 Mar; 113(3):484-493. PubMed ID: 29143400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal.
    Mundin G; McDonald R; Smith K; Harris S; Strang J
    Addiction; 2017 Sep; 112(9):1647-1652. PubMed ID: 28430384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems.
    Elzey MJ; Fudin J; Edwards ES
    Expert Opin Drug Deliv; 2017 Sep; 14(9):1045-1058. PubMed ID: 27606669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. President's message: Food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: What is a treatment advocate and educator to do?
    Morrone WR
    J Addict Dis; 2016; 35(4):339-345. PubMed ID: 27731792
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations.
    Avetian GK; Fiuty P; Mazzella S; Koppa D; Heye V; Hebbar P
    Curr Med Res Opin; 2018 Apr; 34(4):573-576. PubMed ID: 28535115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review.
    Ryan SA; Dunne RB
    Pain Manag; 2018 May; 8(3):231-245. PubMed ID: 29683378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database.
    McDonald R; Danielsson Glende Ø; Dale O; Strang J
    Drug Alcohol Rev; 2018 Feb; 37(2):205-215. PubMed ID: 28597483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naloxone Administration by Untrained Community Members.
    Eggleston W; Calleo V; Kim M; Wojcik S
    Pharmacotherapy; 2020 Jan; 40(1):84-88. PubMed ID: 31782193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods.
    Ashrafioun L; Gamble S; Herrmann M; Baciewicz G
    Subst Abus; 2016; 37(1):76-81. PubMed ID: 26514071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal naloxone administration for treatment of opioid overdose.
    Robinson A; Wermeling DP
    Am J Health Syst Pharm; 2014 Dec; 71(24):2129-35. PubMed ID: 25465584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management.
    Dunn KE; Barrett FS; Bigelow GE
    Addict Behav; 2018 Nov; 86():56-60. PubMed ID: 29625751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial.
    Dietze P; Jauncey M; Salmon A; Mohebbi M; Latimer J; van Beek I; McGrath C; Kerr D
    JAMA Netw Open; 2019 Nov; 2(11):e1914977. PubMed ID: 31722024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal Naloxone for Opioid Overdose.
    Taylor JL; Lasser KE
    JAMA; 2024 Jan; 331(3):250-251. PubMed ID: 38127361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers.
    Skulberg AK; Tylleskar I; Nilsen T; Skarra S; Salvesen Ø; Sand T; Loftsson T; Dale O
    Eur J Clin Pharmacol; 2018 Jul; 74(7):873-883. PubMed ID: 29568976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing methods of naloxone administration: A narrative review.
    Fellows SE; Coppola AJ; Gandhi MA
    J Opioid Manag; 2017; 13(4):253-260. PubMed ID: 28953317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized usability assessment of simulated naloxone administration by community members.
    Eggleston W; Podolak C; Sullivan RW; Pacelli L; Keenan M; Wojcik S
    Addiction; 2018 Dec; 113(12):2300-2304. PubMed ID: 30107641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.